Diphereline PR Dosage/Direction for Use

Posology: Prostate cancer: Duration of the treatment: In high-risk localised or 'locally advanced hormone-dependent prostate cancer as concomitant to and following radiation therapy' clinical data have shown that radiotherapy followed by long-term androgen deprivation therapy is preferable to radiotherapy followed by short-term androgen deprivation therapy (see Pharmacology: Pharmacodynamics under Actions).
The treatment duration of androgen deprivation therapy recommended by medical guidances for patients with high-risk localised or locally advanced prostate cancer receiving radiotherapy is 2-3 years.
In patients who are not surgically castrated and treated with GnRH analogues for metastatic prostate cancer, treatment is usually continued upon development of castrate-resistant prostate cancer.
3.75 mg: One intramuscular injection of Diphereline P.R. 3.75 mg every 4 weeks.
11.25 mg: One intramuscular or subcutaneous injection of Diphereline P.R. 11.25 mg every 3 months.
Endrometriosis: The treatment must be initiated in the first five days of the menstrual cycle.
Duration of treatment: This depends on the initial severity of the endometriosis and the changes observed in the clinical features (functional and anatomical) during treatment. The treatment should not be administered for more than 6 months (see Adverse Reactions). It is not recommended to undertake a second course of treatment by triptorelin or by another GnRH analogue. In patients treated with GnRH analogues for endometriosis, the addition of hormone replacement therapy an add-back therapy (ABT - an estrogen and progestogen) has been shown to reduce bone mineral density loss and vasomotor symptoms. Therefore, if appropriate, ABT should be co-administered with GnRH analogue taking into account the risks and benefits of each treatment.
3.75 mg: One intramuscular injection of Diphereline PR 3.75 mg every 4 weeks.
11.25 mg: One intramuscular injection of Diphereline P.R. 11.25 mg every 3 months.
The subcutaneous administration has not been studied in women.
Central precocious puberty: The treatment of children with triptorelin should be under the overall supervision of the paediatric endocrinologist or of a paediatrician or endocrinologist with expertise in the treatment of central precocious puberty.
3.75 mg: Children under 20 kg in body weight: half (1/2) a dose by intramuscular route, every 4 weeks (28 days), i.e. administer half the volume of the reconstituted suspension.
Children between 20 and 30 kg in body weight: two-thirds (2/3) of the dose by intramuscular route, every 4 weeks (28 days), i.e. administer two-thirds of the volume of the reconstituted suspension.
Children over 30 kg in body weight: one intramuscular injection every 4 weeks (28 days), i.e. administer the full volume of reconstituted suspension.
11.25 mg: Children over 20 kg in body weight: One intramuscular injection of Diphereline P.R. 11.25 mg administered every 3 months.
Diphereline P.R. 11.25 mg must not be injected intravascularly. The subcutaneous administration has not been studied in children.
Treatment should be stopped around the physiological age of puberty in boys and girls and it is recommended that treatment is not continued in girls with bone maturation of more than 12 to 13 years. There are limited data available in boys relating to the optimum time to stop treatment based on bone age, however it is advised that treatment is stopped in boys with a bone maturation age of 13 to 14 years.
Treatment of uterine fibromyomas prior to surgery: 3.75 mg: One intramuscular injection of Diphereline PR 3.75 mg every 4 weeks. The treatment must be initiated in the first five days of the menstrual cycle. Clinical studies were conducted for durations between 3 to 4 months.
Breast Cancer: 3.75 mg: One intramuscular injection every 4 weeks in combination with tamoxifen or an aromatase inhibitor.
Triptorelin should be commenced after completion of chemotherapy, once pre-menopausal status has been confirmed.
The treatment with triptorelin must be initiated at least 6-8 weeks before starting aromatase inhibitor treatment. A minimum of two injections of triptorelin (with an interval of 4 weeks between injections) should be administered before commencement of aromatase inhibitor treatment.
During treatment with an aromatase inhibitor, triptorelin must not be interrupted to avoid rebound increases in circulating oestrogens in premenopausal women.
The recommended treatment duration for adjuvant treatment in combination with other hormonotherapy is up to 5 years.
Method of administration: See as previously mentioned in Posology.
3.75 mg: Since Diphereline P.R. 3.75 mg is a suspension of microparticles, inadvertent intravascular injection must be strictly avoided.
NB: The sustained release form must be injected in strict compliance with the instructions given in the package leaflet. Any incomplete injection resulting in the loss of suspension volume greater than the volume generally remaining in the injection device must be reported.
11.25 mg: For reconstitution of Diphereline before use, see Instructions for Use under Patient Counselling Information.
NB: The prolonged release form must be injected in strict compliance with the instructions given in the package insert. Any incomplete injections resulting in the loss of suspension volumes greater than the volume generally remaining in the injection syringe must be reported.